ASX Announcement

25th November 2020

Reminder: Antisense Therapeutics SPP Closing Date

- Share Purchase Plan Closing Date – Thursday 26 November;
- SPP funds to supplement recently completed $7.3m Placement

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] wishes to remind and confirm to Eligible Shareholders that its share purchase plan (SPP) announced on 11 November 2020, will close as scheduled on 26 November 2020 at 5pm Sydney time (Closing Date).

The SPP provides each eligible shareholder with the opportunity to apply for up to A$30,000 worth of New Shares at the same price ($0.10 per share) as recently completed $7.3 million Placement. Participation in the SPP is voluntary. The SPP is not underwritten.

If you have any queries in relation to the SPP, please contact the Company's share registry Boardroom Limited:

Within Australia: 1300 737 760
Outside Australia: +61 2 9290 9600
Email: corporateactions@boardroomlimited.com.au

Eligible Shareholders can also download their Application Form online at www.investorserve.com.au

Funds raised from the Placement and SPP are to be used for the manufacturing of the drug compound and clinical supplies for the upcoming planned Phase IIb European clinical trial of ATL1102 in DMD; preparatory work for the trial including interactions with EU regulatory consultants and authorities; advancing plans with the US FDA for ATL1102 in DMD including interactions with US regulatory consultants and meeting(s) with the FDA; advancing new indication initiatives for ATL1102 including potential animal pharmacology studies and associated costs for the filing of new possible IP; and general working capital.

This announcement has been authorised for release by the CEO.

For more information please contact:

Antisense Therapeutics
Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.